Fierce Innovation Awards: Life Sciences Edition Announce Finalists, Mercator MedSystems Recognized

EMERYVILLE, Calif., Dec. 16, 2016 /PRNewswire-USNewswire/ -- Mercator MedSystems Inc., a medical technology company focused on the treatment of peripheral artery disease (PAD), announced today that is has been selected as a finalist in this year's Fierce Innovation Awards:  Life Sciences Edition, an awards program from the publisher of FierceBiotech and FiercePharma.  Mercator MedSystems was recognized as a finalist in the category of Drug Delivery Technology.

Mercator was selected as a finalist for its Bullfrog® Micro-Infusion Device, an FDA 510(k)-cleared and CE-Marked system designed to infuse therapeutic and diagnostic agents directly, non-systemically and safely through blood vessel walls into adventitial and perivascular tissues. 

"We are honored to be receiving industry recognition for our Bullfrog Micro-Infusion Device and to be named a finalist among such an outstanding field of innovative companies in the drug delivery technology space," said Trent Reutiman, CEO of Mercator MedSystems.  "It's significant validation of our mission to set a new and more cost-effective standard of care for the prevention of restenosis in patients with PAD, including those who have progressed to critical limb ischemia (CLI)."

The Bullfrog Device is being tested as part of a new anti-inflammatory treatment strategy for stopping scar tissue buildup and restenosis to keep blood flowing into the legs and feet after a balloon angioplasty or atherectomy.  This is done by locally delivering dexamethasone (a generic anti-inflammatory steroid) to the adventitia using the Bullfrog Device.  The intent of the therapy is to stop the inflammation and weaken the biologic signals that normally lead to restenosis.  This may delay repeat procedures and reduce amputations in patients with PAD or CLI.

Finalists' applications were reviewed by an exclusive panel of executives from Medidata, PwC, PPD, Amgen and more. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact and true innovation. Full profiles of the judges can be found at https://www.fierceinnovationawards.com/life-science/2016#our_judges. 

Winners will be announced on Wednesday, December 21 at 2:00 P.M. during a Live Awards Webcast.  Register to attend here.

About FierceMarkets
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, finance, and retail industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries. 

Current publications include:  Telecom: FierceWireless; FierceCable; FierceDeveloper; FierceOnlineVideo; FierceTelecom; FierceWirelessTech; FierceWireless:Europe /TelecomsEMEA,  FierceInstaller; an Telecom Asia; Healthcare: FierceEMR; FierceHealthcare; FierceHealthFinance; FierceHealthIT; FierceHealthPayer; FierceHealthPayerAntiFraud; FierceMobileHealthcare; FiercePracticeManagement and Hospital Impact; Life Sciences: FierceBiotech; FierceBiotechIT; FierceBiotech Research; FierceCRO; FierceDiagnostics, FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaAsia; FiercePharmaMarketing; FiercePharmaManufacturing; FierceVaccines and FierceAnimalHealth Enterprise IT: FierceBigData; FierceCIO; FierceContentManagement; FierceDevOps; FierceEnterpriseCommunications; FierceITSecurity and FierceMobileIT; Finance: FierceCFO; and FierceFinanceIT; Government: FierceGovernment; FierceGovernmentIT; FierceHomelandSecurity; FierceMobileGovernment; FierceCities and FierceGovHealthIT Marketing & Retail: FierceCMO; FierceTechExec.

About Mercator MedSystems
Mercator MedSystems, Inc., based in Emeryville, CA, is a venture-backed, privately held medical technology company delivering innovative, customizable, treatment solutions for intractable problems associated with some of the world's most significant diseases. The company develops catheter-guided micro-infusion systems for targeted delivery of drugs and biologics deep inside the body to treat the root cause of a growing portfolio of medical conditions, including cardiovascular disease, cancer, hypertension and heart disease.  For more information, visit Mercatormed.com

For Media Inquiries:
Lori Rosen
[email protected]
917-553-6808

SOURCE Mercator MedSystems

Related Links

http://www.mercatormed.com